Contact Us

Request a Demo

Condition

Advanced Solid Tumors(1)

BRAF-Mutated Melanoma(1)

Colorectal Carcinoma(1)

EGFR Positive Non-small Cell Lung Cancer(1)

Recurrent Ovarian Carcinoma(1)

Overall Status

Active, not recruiting(1)

Phase

phase 1(1)

Sponsor New

Sumitomo Pharma Oncology, Inc.(1)

Intervention New

tp-0903(1)

Study Results

Has Results

Study Documents

Intervention Type

drug(1)

Funder Type

Industry(1)

Study Type

Interventional(1)

Age Group

Any

Youth (0 - 17 years)

Adult (18 - 64 years)

Older Adult (65+ years)

Gender

all(1)

City

Jacksonville(1)

BRAF Mutated Melanoma Clinical Trials

Create an account to Download

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

S

First-in-human Study of Oral TP-0903 (a Novel Inhibitor of AXL Kinase) in Patients With Advanced Solid Tumors

Active, not recruiting

Advanced Solid Tumors
+4 more

TP-0903

Phoenix, Arizona
+15 more

2022-04-04

Apr 4, 2022

Do More

Create up to 2 groups of studies for comparison and sharing
Get notified when studies are updated
Download tabulated search results instantly
Unlimited searches

Sign UpNot Today

2022 © Clincosm, Inc.

Exploring the universe of clinical trials just got cosmically easier.

Newest Clinical Trials